Title: Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach
Abstract: CancerVolume 75, Issue 2 p. 451-456 ArticleFree Access Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach Yeul H. Kim M.D., Yeul H. Kim M.D. Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this authorJaffer A. Ajani M.D., Corresponding Author Jaffer A. Ajani M.D. Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TexasThe University of Texas M. D. Anderson Cancer Center, Box 78, 1515 Holcombe Boulevard, Houston, TX 77030-4095===Search for more papers by this authorDavid M. Ota M.D., David M. Ota M.D. Department of General Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this authorPatrick Lynch M.D., Patrick Lynch M.D. Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this authorJack A. Roth M.D., Jack A. Roth M.D. Department of Thoracic Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this author Yeul H. Kim M.D., Yeul H. Kim M.D. Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this authorJaffer A. Ajani M.D., Corresponding Author Jaffer A. Ajani M.D. Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TexasThe University of Texas M. D. Anderson Cancer Center, Box 78, 1515 Holcombe Boulevard, Houston, TX 77030-4095===Search for more papers by this authorDavid M. Ota M.D., David M. Ota M.D. Department of General Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this authorPatrick Lynch M.D., Patrick Lynch M.D. Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this authorJack A. Roth M.D., Jack A. Roth M.D. Department of Thoracic Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TexasSearch for more papers by this author First published: 15 January 1995 https://doi.org/10.1002/1097-0142(19950115)75:2<451::AID-CNCR2820750207>3.0.CO;2-UCitations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5-year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2% (20/90); after chemotherapy, it dropped to 10.9% (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre- and postchemotherapy CEA-positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti-CEA antibodies may prove useful for certain groups of patients. Cancer 1995;75:451-6. References 1 Boring CC, Squires TS, Tong T. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7– 26. 2 Adashek K, Sanger J, Longmire WP. Cancer of the stomach: review of consecutive ten year intervals. Ann Surg 1979; 189: 6– 10. 3 Andaker L, Morales O, Höjer H, Bäckstrand B, Borch K, Larsson J. Evaluation of preoperative computed tomography in gastric malignancy. Surgery 1991; 109: 132– 5 4 Diehl JT, Hermann RE, Cooperman AM, Hoerr SO. Gastric carcinoma:a ten-year review. Ann Surg 1983; 198: 9– 12. 5 McBride CM, Boddie AW. Adenocarcinoma of the stomach: are we making any progress? South Med J 1987; 80: 283– 6. 6 Bizer LS. Adenocarcinoma of the stomach: current results of treatment. Cancer 1983; 51: 743– 5. 7 The Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116– 22. 8 Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma: a Veterans Administration Surgical Oncology Group report. Cancer 1983; 52: 1105– 12. 9 Engstrom PF, Lavin PT, Douglass HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients: Eastern Cooperative Oncology Group Study (EST 3275). Cancer 1985; 55: 1868– 73. 10 Douglass HO. Gastric cancer: current status of adjuvant therapy. Oncology 1989; 3: 61– 77. 11 Giuli R, Gignoux M. Treatment of carcinoma of the esophagus: retrospective study of 2400 patients. Ann Surg 1980; 192: 44– 52. 12 Xu LT, Sun ZF, Li ZJ, Wu LH. Surgical treatment of carcinoma of the esophagus and cardiac portion of the stomach in 850 patients. Ann Thorac Surg 1983; 35: 542– 7. 13 Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinomas. J Natl Cancer Inst 1993; 85: 1839– 44. 14 Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990; 8: 1231– 8. 15 Wilke H, Preusser P, Fink U, Gunzer U, Meyer H-J, Meyer J, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318– 26. 16 Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Husted S, Takasugi BJ, et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990; 8: 119– 27. 17 Holyoke ED, Chu TM, Murphy GP. CEA as a monitor of gastrointestinal malignancy. Cancer 1975; 35: 830– 6. 18 Staab HJ, Anderer FA, Brummendorf T, Fischer R. Prognostic significance of preoperative carcinoembryonic antigen in stomach and colorectal cancer. Cancer Detect Prev 1983; 6: 149– 53. 19 Koga T, Kano T, Souda K, Oka N, Inokuchi K. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg 1987; 17: 342– 7. 20 Staab HJ, Anderer FA, Brummendorf T, Hornung A, Fischer R. Prognostic value of preoperative serum CEA level compared to clinical staging: II.: Stomach cancer. Br J Cancer 1982; 45: 718– 27. 21 Roberts PJ, Haglund C, Onali M, Kuusela P. Tumor markers in gastric cancer Ann Chir Gynaecol 1989; 78: 38– 40. 22 Imamura Y, Yasutake K, Yoshimura Y, Oya M, Matsushita K, Tokisue M, et al. The changes in tumor markers such as serum CEA,CA 19-9,TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer. Jpn J Cancer Chemother 1990; 17: 1501– 7. 23 Saito D, Yoshida S, Hijikata A, Tajiri H, Yamaguchi H, Yoshimori M, et al. The relation between serum carcinoembryonic antigens and response to chemotherapy in patients with advanced gastric cancer. J Jpn Soc Cancer Ther 1987; 22: 948– 57. 24 Sorokin JJ, Sugarbaker PH, Zamcheck N, Pisick M, Kupchik HZ, Moore FD. Serial carcinoembryonic antigen assays: use in detection of cancer recurrence. JAMA 1974; 228: 49– 53. 25 Ellis DJ, Speirs C, Kingston RD, Brookes VS, Leonard J, Dykes PW. Carcinoembryonic antigen levels in advanced gastric carcinoma. Cancer 1978; 42: 623– 5. 26 Kano T, Koga T, Souda K, Abe Y, Yonemura T, Oka N, et al. The usefulness of CEA as an indicator for early detection and a guide to the treatment of recurrent gastric cancer. Jpn J Surg 1987; 17: 269– 75. 27 Tamada R, Hiramoto Y, Abe Y, Notsuka T, Okamura T, Masuda H, et al. Serial determinations of carcinoembryonic antigen for early detection of recurrent gastric cancer. Jpn J Surg 1982; 12: 429– 33. 28 Janssen CW Jr., Orjasaeter H. Carcinoembryonic antigen in patients with gastric carcinoma. Eur J Surg Oncol 1986; 12: 19– 23. 29 Nanus DM, Kelsen DP, Niedzwiecki D, Chapman D, Brennan M, Cheng E, et al. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Oncol 1989; 7: 1105– 12. 30 Barillari P, Sammartino P, Cardi M, Ricci M, Gozzo P, Cesareo S, et al. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and CA 19-9 evaluation in the early diagnosis of recurrences. Aust N Z J Surg 1991; 61: 675– 80. 31 Shimizu N, Wakatsuki T, Murakami A, Yoshioka H, Hamazoe R, Kanayama H, et al. Carcinoembryonic antigen in gastric cancer patients. Oncology 1987; 44: 240– 4. Citing Literature Volume75, Issue215 January 1995Pages 451-456 ReferencesRelatedInformation